All Pharma News
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study

Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study
PR NEWSWIRE
12 Dec 2023
Share Share
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH

Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH
PRESS RELEASE
11 Dec 2023
Share Share
Curis Announces Three Presentations at ASH

Curis Announces Three Presentations at ASH
PRESS RELEASE
06 Dec 2023
Share Share
Curis Enters into Agreement for Emavusertib Combination Study in Melanoma

Curis Enters into Agreement for Emavusertib Combination Study in Melanoma
PR NEWSWIRE
05 Dec 2023
Share Share
Curis Provides Third Quarter 2023 Business Update

Curis Provides Third Quarter 2023 Business Update
PRESS RELEASE
02 Nov 2023
Share Share
FDA lifts partial hold on Curis` PhI/II leukemia study as biotech raises $15M 

FDA lifts partial hold on Curis` PhI/II leukemia study as biotech raises $15M 
Paul Schloesser ENDPTS
07 Jul 2023
Share Share
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NEWSWIRE
05 Apr 2023
Share Share
FDA puts Curis` leukemia trial on partial hold after patient death

FDA puts Curis` leukemia trial on partial hold after patient death
Nick Paul Taylor FIERCE BIOTECH
04 Apr 2023
Share Share
Curis Provides Fourth Quarter 2022 Business Update

Curis Provides Fourth Quarter 2022 Business Update
PR NEWSWIRE
13 Mar 2023
Share Share
Curis shrinks headcount by 30% as execs place bigger hopes on blood cancer drug

Curis shrinks headcount by 30% as execs place bigger hopes on blood cancer drug
Amber Tong ENDPTS
11 Nov 2022
Share Share